Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.45 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896230 | 1.00 | GABBR2 (0.45) | GABBR2GABBR1EPHX1METAP2LMNA | |
| SCHEMBL6898546 | 0.81 | IDO1 (0.42) | METAP2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6899688 | 0.81 | IDO1 (0.42) | METAP2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6898544 | 0.81 | IDO1 (0.42) | METAP2LMNAMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL6898738 | 0.80 | IDO1 (0.44) | METAP2LMNAMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL6898731 | 0.80 | IDO1 (0.44) | METAP2LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6891284 | 0.76 | EPHX1 (0.52) | GABBR2GABBR1EPHX1METAP2SLC6A2 | |
| SCHEMBL6891293 | 0.76 | EPHX1 (0.52) | GABBR2GABBR1EPHX1METAP2SLC6A2 | |
| SCHEMBL6896284 | 0.75 | SLC6A2 (0.47) | EPHX1LMNAMEN1HTTKMT2A | |
| SCHEMBL6897515 | 0.75 | SLC6A2 (0.47) | EPHX1LMNAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317461-B1 | 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES | SCHERING CORP (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1317461-A1 | 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES | SCHERING CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6509472-B2 | For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols | SCHERING CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-20020038053-A1 | For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols | SCHERING CORPORATION | 2002-03-28 | — | — | US | disclosed |
| WO-2002022623-A1 | 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES | SCHERING CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038053-A1 | For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols | ADH5, ADH1A, ADH1C | GABBR2 978/4885GABBR1 786/4885EPHX1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.